Working… Menu

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00310336
Recruitment Status : Completed
First Posted : April 3, 2006
Last Update Posted : October 28, 2010
Information provided by:
University Hospital, Basel, Switzerland

Brief Summary:

50-60% of patients with chronic hepatitis C are not cured by treatment with pegylated IFNα plus ribavirin.

Retreatment of non-responders of previous (pegylated) IFNα plus ribavirin therapies with pegylated IFNα plus ribavirin results in a sustained response in less than 10% of the patients.

Extensive analysis of IFNα signaling in cells expressing HCV proteins, in transgenic mice expressing HCV proteins, and in liver biopsies from patients with chronic hepatitis C point to STAT1 methylation as an important posttranslational modification targeted by HCV to inhibit IFNα signaling.

STAT1 methylation can be increased and IFNα can be improved by adding AdoMet and betaine.

The study is designed to test the hypothesis that a combination treatment with pegylated IFNα2b, ribavirin, AdoMet and betaine is superior to the current standard combination therapy with pegylated IFNα plus ribavirin.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: S-adenosyl-L-methionine Drug: betaine Drug: pegylated interferon alpha2b Drug: ribavirin Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine
Study Start Date : August 2006
Actual Primary Completion Date : August 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Sustained response rate

Secondary Outcome Measures :
  1. Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female between 18 and 65 years.
  • Non-responders in previous treatments with IFNα plus ribavirin or pegylated IFNα plus ribavirin.
  • Elevated ALT-levels on at least two occasions during >6 months preceding entry.
  • Detection of HCV RNA in serum (PCR).
  • Compensated liver disease (Child-Pugh A) and a Child-Pugh score <5.
  • The following minimal hematologic and biochemical criteria:
  • Hemoglobin for males and females >11g/dl
  • Absolute Neutrophil count >1500 cells/mm3
  • Platelets >75'000/mm3
  • HBs Ag negative.
  • ANA <1:320, and no evidence for autoimmune hepatitis.
  • α-Fetoprotein <50μg/l (when between upper limit of normal and 50μg/l, ultrasonographical exclusion of hepatocellular carcinoma (HCC) is needed).
  • Fasting blood glucose within normal limits, if history of diabetes or hypertension, a pre-therapy ocular examination is indicated.
  • TSH within normal limits or adequately controlled.
  • Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 2-3 week period prior to the first dose of study drug. Additionally, all fertile males and females must be using effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
  • Willingness to give written informed consent and willingness to participate to and comply with the study

Exclusion Criteria:

  • Women with ongoing pregnancy or breast feeding.
  • Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBe Ag.
  • Positive test at screening for HIV.
  • History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures).
  • Hypersensitivity to study drugs.
  • Participation in any other clinical trial within 30 days of entry into this protocol.
  • Treatment with any investigational drug within 30 days of entry into this protocol.
  • History or evidence of decompensated liver disease (Child-Pugh B/C) and a Child-Pugh score >5. Ascites, coagulopathy, hyperbilirubinemia, hepatic encephalopathy, or hypoalbuminemia and a Child-Pugh score >5 are conditions consistent with decompensated liver disease.
  • History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease.
  • Hepatocellular carcinoma (HCC) or α-Fetoprotein >50μg/l.
  • Patients with organ transplants other than cornea and hair transplant.
  • Therapy with any antisystemic or immunomodulatory treatment (including supra-physiologic doses of steroids or radiation) <6 months prior the first dose of study drug
  • Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis.
  • Any known preexisting medical condition that could interfere with the patient's participation in and completion of the study such as:
  • Preexisting psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychosis, suicidal ideation and/or suicidal attempts (based on a mandatory psychiatric advice).
  • CNS trauma or active seizure disorders requiring medication.
  • Significant cardiovascular dysfunction.
  • Poorly controlled diabetes mellitus.
  • Renal dysfunction, i.e. serum creatinine levels >1.5 times upper limit of normal.
  • Autoimmune diseases.
  • Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration).
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids.
  • Clinical gout.
  • Important substance abuse (alcohol >80 g/d, i.v. drugs etc.).
  • Active opportunistic infections.
  • Non-Hodgkin lymphoma or Hodgkin lymphoma.
  • Kaposi sarcoma.
  • Inability or unwillingness to provide informed consent or abide by the requirements of the study.
  • Male partners of pregnant women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00310336

Layout table for location information
University Hospital Basel
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Layout table for investigator information
Principal Investigator: Markus H Heim, MD University Hospital, Basel, Switzerland
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00310336    
Other Study ID Numbers: EKBB 37/06
First Posted: April 3, 2006    Key Record Dates
Last Update Posted: October 28, 2010
Last Verified: October 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Interferon alpha-2
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Gastrointestinal Agents
Lipotropic Agents
Hypolipidemic Agents
Lipid Regulating Agents